Monitoring immunomodulation strategies in type 1 diabetes

Area of Science:

• Immunology
• Endocrinology
• Autoimmune Diseases

Background:

• Type 1 diabetes (T1D) is a T-cell mediated autoimmune condition.
• Current immunotherapies targeting immune cells and cytokines provide only short-term disease modification.
• Understanding T-cell responses is crucial for T1D management.

Purpose of the Study:

• To review lessons learned from T1D immunomodulatory trials.
• To discuss advancements in analyzing antigen-specific T cells.
• To highlight the potential of novel biomarkers and assays for T1D prediction and treatment.

Main Methods:

• Review of short-term treatment trials for T1D.
• Analysis of progress in antigen-specific T cell assays and epitope discovery.
• Discussion of high-dimensional profiling (gene, protein, TCR) at the single-cell level.

Main Results:

• Short-term immunomodulatory treatments can temporarily halt T1D activity.
• Standardization of T cell assays and epitope discovery face challenges.
• High-dimensional single-cell profiling offers promise for biomarker discovery.

Conclusions:

• Effective disease-modifying agents for early-stage T1D are anticipated.
• Evolving assays for antigen-specific T cells will improve T1D prediction.
• Enhanced understanding of T cell responses will guide therapeutic interventions for T1D.